ictastan 200 mg/245 mg film-coated tablets
actavis group ptc ehf - emtricitabine; tenofovir disoproxil - film-coated tablet - 200/245 milligram(s) - antivirals for treatment of hiv infections, combinations; tenofovir disoproxil and emtricitabine
emtricitabine/tenofovir disoproxil 200 mg/245 mg film-coated tablets
accord healthcare limited - tenofovir disoproxil; emtricitabine - film-coated tablet - 200mg/245 milligram(s) - antivirals for treatment of hiv infections, combinations; tenofovir disoproxil and emtricitabine
abacavir/lamivudine 600 mg/300 mg film-coated tablets
accord healthcare limited - abacavir; lamivudine - film-coated tablet - 600/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir
efavirenz/emtricitabine/tenofovir disoproxil zentiva
zentiva k.s. - efavirenz, emtricitabine, tenofovir disoproxil, phosphate - hiv infections - antivirals for systemic use, - efavirenz/emtricitabine/tenofovir disoproxil zentiva is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. it is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults aged 18 years and over with virologic suppression to hiv-1 rna levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in efavirenz/emtricitabine/tenofovir disoproxil zentiva prior to initiation of their first antiretroviral treatment regimen., the demonstration of the benefit of the combination efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavir
abacavir/lamivudine 600 mg/300 mg film-coated tablets
accord healthcare ireland ltd. - abacavir; lamivudine - film-coated tablet - 600 mg/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir
lopinavir/ritonavir mylan
mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.
zepatier
merck sharp & dohme b.v. - elbasvir, grazoprevir - hepatitis c, chronic - direct acting antivirals, antivirals for systemic use, , antivirals for treatment of hcv infections - zepatier is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg (see sections 4.2, 4.4 and 5.1). for hepatitis c virus (hcv) genotype-specific activity see sections 4.4 and 5.1.,
kivexa tablets film-coated
glaxo wellcome s.a. - abacavir (abacavir sulfate), lamivudine - tablets film-coated - 600mg+ 300mg
aciclovir 250mg powder for solution for infusion vials
wockhardt uk ltd - aciclovir sodium - powder for solution for infusion - 250mg
acyclovir denk 200 tablets
denk pharma gmbh & co. kg - aciclovir - tablets - 200mg